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Objective. The optimal management of pediatric patients with arterial ischemic stroke (AIS) is not known. Despite this, goal-
oriented, time-sensitive therapies geared to rapid reestablishment of arterial blood ﬂow are occasionally applied with beneﬁcial
eﬀects. The inconsistent approach to AIS is in part due to a lack of knowledge and preparedness. Methods. Case report of a 12-
year-old male with right middle cerebral artery (MCA) occlusion resulting in dense left hemiplegia and mutism and review of the
literature. Intervention(s). Mechanical thrombectomy, intra-arterial administration of rt-PA, vasodilators, and platelet inhibitors,
and systemic anticoagulation and subsequent critical care support. Results. Restoration of right MCA blood ﬂow and complete
resolution of neurologic deﬁcits. Conclusion. We report the gratifying outcome of treatment of a case of AIS in a pediatric patient
treated with hyperacute therapies geared to arterial recanalization and subsequent neurologic critical care and review the pertinent
literature. Guidelines for the emergency room management of pediatric AIS from prospective, randomized trials are needed.
1.Introduction
Arterial ischemic stroke (AIS) occurs more commonly in
adults than children. In children the clinical presentation
is often interpreted as other neurologic conditions or
intoxications resulting in a delay in diagnosis due to the
lack of awareness of pediatrician or that the symptoms do
not systematically evoke a stroke. Adult AIS occurs in the
setting of the principal risk factors of hypertension and
atherosclerosis,whilepediatricriskfactorsareheterogeneous
and include focal intracranial arteriopathies, congenital car-
diovascular diseases, and hemoglobinopathies [1, 2]. Recent
advances in the management of AIS have emphasized the
importance of timely diagnosis and restoration of arterial
ﬂow in the aﬀected vascular territories. Adult victims have
access to time-sensitive or hyperacute therapies due to an
awareness of the severity of the disease, organization of
delivery of medical care from the emergency room that
includes designation of stroke centers, and protocol-driven
preparedness for such emergencies [3–6]. Unfortunately, this
is not the case for pediatric victims, because it is not known
whether thrombolytic therapies are appropriate.
We describe the case of a 12-year-old male with AIS
who presented to medical attention with a potentially
devastating neurological injury. A resolute strategy utilizing
hyperacute therapies aimed at restoring blood ﬂow followed
by neurointensive care support was provided. The patient
had a very good outcome that may be related to this
management but a complete causation cannot be ascribed
to it as 1 out of 3 patients with lenticulostriate stroke may
h a v eas p o n t a n e o u sf a v o r a b l ee v o l u t i o n .H e r e i nw er e v i e w
the literature to date describing the challenges in analyzing
and preparing for the application of time-sensitive therapies
in the treatment of AIS.
2.CaseReport
The institutional IRB was consulted and waved the need
for approval of the publication of this case. The patient is
a 12-year-old, right-handed, 52kg African-American male2 Neurology Research International
Figure 1: Diﬀusion weighted imaging (DWI) showing area of
restricted diﬀusion.
without any signiﬁcant medical history other than nocturnal
enuresis. His father woke him up at 04:00 on the morning
of admission as was customary in their home to prevent
bedwetting. While initially he responded appropriately, the
child collapsed to the ground after standing and became
unresponsive. He was transported to an outlying emergency
department where he was noted to have aphasia and left
dense hemiplegia. Computed tomography demonstrated
signal attenuation and edema in the vascular distribution
of the right middle cerebral artery. Right lateral ventricle
compression and midline shift were noted.
The patient was transferred to our institution by heli-
copter and was brieﬂy examined in the emergency room
prior to transfer to the magnetic resonance (MR) imaging
suite. He was awake, with stable airway, anxious and
frustrated by inability to speak, but was cooperative and able
to follow some commands. Heart rate was 50–60 beats per
minute and blood pressure was 130–140/80–90mmHg. He
demonstrated lack of language expression, ﬂaccid paralysis
of the left face, upper extremity, and lower extremity. His
NIH stroke score was 16. MRI and MRA studies revealed
occlusion of the right middle cerebral artery with restricted
diﬀusion in the right basal ganglia and the posterior lateral
aspect of the caudate head (Figure 1). There was mass
eﬀect on the right lateral ventricle and midline shift. Our
information was that 6h had elapsed since the onset of
neurologic symptoms. Taking into account the possibility of
a devastating clinical outcome and in conjunction with adult
stroke and interventional radiologist specialist, the decision
was made to attempt to restore arterial patency.
The patient was anesthetized, intubated, and cooled
to 33–35
◦C (mild therapeutic hypothermia). A thrombus
was located (Figures 2 and 3); endovascular mechanical
e m b o l e c t o m yw i t haM e r c ir e t r i e v a ld e v i c ew a sa t t e m p t e d
without success. Recombinant tissue plasminogen activator
(rt-PA) was infused into the MCA in doses of 0.7, 2, and
4mg with minimal improvement in blood ﬂow. Abciximab
and nitroglycerin (25µg) were then infused with consider-
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Figure 2: Coronal view of angiography arrow pointing to the area
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Figure 3: Sagittal view of angiography arrow pointing to the area
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Figure 4: Sagittal view demonstrating a signiﬁcant improvement in
blood ﬂow after rt-PA Abciximab and nitroglycerin were infused.
Arrow points to a small residual occlusion.Neurology Research International 3
The patient was transferred to the pediatric ICU and
remained sedated and mechanically ventilated. Neurosurgi-
cal consultation was obtained for an intracranial pressure
(ICP) monitoring, but this was not placed due to recent
thrombolytic administration and the initiation of systemic
anticoagulation.Heparinwasadministeredfor7days,Abcix-
imab (10µg/min for the ﬁrst 12h), aspirin (325mg/day),
magnesium sulfate (2000mg/24hrs), 25% albumin (1g/kg
IV every 6h for the ﬁrst 5 days), and memantine HCL
(10mg nasogastric each day for 3 days). Mild therapeutic
hypothermia was maintained for 4 days to decrease acute
postischemic cerebral edema followed by passive rewarming
over a 24-hour period. A CT scan obtained at 24hrs showed
a decrease in the midline shift.
The central venous pressure (CVP) was maintained
at 8–10cm H2O and mean arterial pressure (MAP) at
75–80mmHg. A dual channel near infrared spectroscopy
(NIRS) probe was applied to the scalp overlying both frontal
lobes. Initially, there was a discrepancy between the two sides
with the ischemic right side 10%–15% lower than the left
side (40%–50% versus 65%–70%). Increasing CVP or MAP
served only to augment the discrepancy. Subsequently, the
partial pressure of arterial carbon dioxide was allowed to
increase from 35–40 to 46–55mmHg with resolution of the
discrepancy (both sides equal to 60%–65%).
M Rs t u d i e so nt h e7 t hd a yr e v e a l e da p p r o p r i a t eM C A
blood ﬂow and partial resolution of the ischemic changes
in the basal ganglia. Mass eﬀect and right lateral ventricle
compression by the basal ganglia were improved. He was
extubated on day 10 and was able to communicate verbally,
written, and receptive but had a small degree of residual left
hemiparesis. He was transferred to a rehabilitation facility
on day 15 where he exhibited an almost complete recovery
within the following two weeks and was discharged home.
Subsequent followup by our pediatric neurology service
over the next year has demonstrated complete recovery
to baseline without deﬁcits. One year later he is taking
advanced placement classes in school, playing junior high
school basketball and baseball, and having no demonstrable
neurological deﬁcits.
Cerebral angiography and serologic studies did not ﬁnd
thepresenceofdissection,vasculitis,orautoimmunedisease;
transthoracic echocardiography ruled out structural heart
disease, intracardiac thrombus, and right to left intracardiac
shunt, and hemoglobin electrophoresis, hypercoagulability
studies, and lipid panels were all unremarkable. Doppler
studies of the veins of the lower extremities and pelvis were
all negative for deep venous thrombosis. An etiology for
this patient AIS has not been found. An MRI performed
3 months after the events showed resolution of the edema
and restricted diﬀusion with a residual hyperdense signal
abnormally in the periventricular region (Figure 6).
3. Discussion
Our case report diﬀers from others in the literature in
that intra-arterial thrombolysis was undertaken 6h after
the onset of symptoms than most other reports of anterior
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Figure 5: Sagittal view demonstrating a signiﬁcant improvement in
blood ﬂow after rt-PA Abciximab and nitroglycerin were infused.











Figure 6: MRI 3 month after the initial insult showing a residual
hyperdense signal abnormally in the periventricular region.
complete a recovery. Several provocative issues relevant to
AIS in children are raised by his management: (a) the use of
hyperacute therapies, (b) the role of antiplatelet agents and
anticoagulants in the management of AIS, and (c) the role of
adjunctive pharmacological neuroprotective agents.
The growing recognition that AIS in adults is reversible if
treatedinapromptmannerhasfosteredasenseofurgencyin
clinicians who regard this condition as a “brain attack” and
hospitals preparedness with designation of stroke centers for
rapid triage and treatment. The resolve of the physician has a
decisive eﬀect on the timely implementation of therapies for
stroke in adults [3].
By comparison, little sense of urgency to aggressively
restore vascular patency exists for pediatric patients, and
with the exception of AIS in the setting of sickle cell disease
andMoyamoyadisease,therapeuticapproachesthatembrace
supportive care and rehabilitation are more common in
pediatric hospitals. Development of a similar sense of4 Neurology Research International
determination and urgency is hampered by several obstacles.
First, pediatric emergency room practitioners encounter
AIS infrequently, and it is therefore not uncommon for
considerable delay to occur in the diagnosis excluding the
patient from the accepted time windows for hyperacute
therapies. Second, the outcome of children with stroke is
incorrectly thought to be better than that of adults. The
outcome of AIS is mainly determined by size, location,
and etiology of stroke. While the pediatric mortality is
described to be between 5%–10% and is favorable when
compared to adult patients, pediatric survivors of AIS are
left with persistent neurologic and psychosocial deﬁcit or
seizure disorder for the rest of their lives [7, 8]. Third,
the pathophysiology underlying the heterogeneous disorders
of pediatric AIS makes it diﬃcult to extrapolate the adult
AIS literature to children, and many children’s hospitals do
not have preplanned algorithms for rapid diagnosis and
treatment of AIS. Finally, many practitioners are uncomfort-
able administering thrombolytic medications in the absence
of pediatric-speciﬁc data or clinical guidelines to support
their use. Indeed, most recommendations for the treatment
of AIS in children are derived from consensus and expert
opinion, and neither the Royal College of Physicians (RCP)
in the United Kingdom nor the American College of Chest
Physicians (ACCP) in the United States recommends the
administration of rt-PA to children with AIS [9, 10]. Despite
this reluctance, several case reports to date have described
their use in children [11–16], and a review of a national
inpatient database registry indicates that a small minority
of pediatric patients with AIS are receiving thrombolytic
therapy [17, 18].
3.1. Thrombolysis/Embolectomy. The term “hyperacute ther-
apies” has been coined to refer to therapies which must be
initiated within an acceptable time interval in order to be
eﬀective,andtheyaredesignedtorestorebloodﬂowthrough
obstructed vascular beds. Hyperacute therapies that are
oﬀered to adults include intravenous thrombolysis with rt-
PA, intra-arterial thrombolysis with rt-PA, and mechanical
embolectomy.
The use of intravenous thrombolysis is now well estab-
lishedintheliteratureandisrecommendedforthetreatment
of AIS in adults without contraindications who present to
medical attention within 3h of symptoms onset [4, 5].
Patients treated with 0.9mg/kg rt-PA (10% as a bolus and
the remainder infused over 1 hour) had better functional
outcomes at 3 months when compared to patients who
received placebo, and mortality rates were similar between
the two groups. Symptomatic intracranial hemorrhage
occurred in 6.4% of patients treated with rt-PA and 0.6% of
controls. The time period from onset of stroke symptoms to
beneﬁcial treatment with thrombolytic medications remains
a subject of continuous debate. The debate addresses the
observation that as time from symptom onset increases the
likelihood of outcome beneﬁt from thrombolysis decreases
while thrombolytic therapy is associated with a substantial
increase in likelihood of intracranial hemorrhage. However,
a recent publication demonstrated beneﬁt while extending
the administration up to 4.5h after the onset of symp-
toms [6]. Furthermore, whether strict adherence to pre-
deﬁned time interval cutoﬀs should be used to determine
whether thrombolytic therapy should be oﬀered is unclear.
Comparison of MRI diﬀusion-weighted imaging (DWI) and
perfusion-weighted imaging (PWI) may allow the clinician
to determine for each patient how much brain tissue is
receiving inadequate blood ﬂow (abnormal PWI) to still
viable brain tissue (intact DWI). Such an examination might
allow clinicians to determine for patients presenting after
more prolonged time intervals from onset of neurologic
symptoms whether thrombolytic therapy could still be
beneﬁcial to a given patient [10, 11, 18, 19].
Intra-arterial administration of thrombolytics (uroki-
nase and rt-PA) is sometimes oﬀered as a potential, viable
alternative for the delivery of thrombolytic medications
to obstructed cerebral vascular beds for patients who are
not candidates for systemic intravenous thrombolysis or
those who present to medical attention between 3 and
6h after symptom onset. Intra-arterial administration of
recombinant prourokinase and intravenous heparin within
6h of onset of stroke symptoms resulted in improved
functional outcomes when compared to intravenous heparin
alone [20], but intra-arterial and intravenous thrombolyses
have not been compared to each other.
Other options for recanalization of obstructed cerebral
vasculature include the use of endovascular mechanical
retrieval devices for clot removal. Intra-arterial and endovas-
cular mechanical embolectomies have extended the time
window for treatment up to 8h for AIS in the anterior
circulation, and even longer in cases involving the posterior
circulation. While mechanical intra-arterial thrombectomy
has demonstrated a high recanalization rate [21], random-
ized trials that describe functional outcome are lacking.
There is evidence that thrombolytic medications are
being administered to 1.6% of the children with AIS, and
this data suggests that children may have inferior clinical
outcomes with respect to mortality [18]. However, it cannot
be determined from this data whether inferior outcomes
are related to AIS severity or the treatment itself. Pediatrics
encompasses a wide range of ages with maturational diﬀer-
ences. Optimal rt-PA dosing is likely to diﬀer as there are
age-dependent diﬀerences in hemostasis [22, 23], younger
individuals demonstrating diminished speciﬁc indices of
ﬁbrinolysis and global, increased ﬁbrinolytic capacity [22].
Case reports over the past eight years have described the
administration of thrombolytic medications to pediatric
patients with good result at widely diﬀerent interval from
onset of symptoms [13, 16, 24–29]. Location of the AIS and
anticipated neurological deﬁcits is a major consideration.
Indeed, due to the dire outcome of vertebrobasilar throm-
bosis (VBT), case reports in the pediatric literature describe
successful administration of thrombolytic therapy 17h after
the onset of symptoms [24, 25].
3.1.1. Anticoagulation and Antiplatelet Therapy. The role
of anticoagulation in pediatric AIS patients is unclear.
The RCP and ACCP guidelines provide recommendations
for acute treatment and secondary prevention of AIS.
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of anticoagulation in the acute management of AIS in
children. RCP guidelines for the management of acute AIS
in children (not associated with intracranial hemorrhage or
sickle cell disease) recommend the administration of aspirin
(5mg/kg/day) [10]. The ACCP guidelines for management
of acute AIS in children have a Class II recommendation
in regard to the initiation of unfractionated heparin or
low-molecular weight heparin (LMWH) for 5–7 days or
until cardioembolic stroke and vascular dissection have
been excluded [2, 9, 10]. Heparin may be safe for the
treatment of strokes secondary to sinovenous thrombosis
e v e nt h o u g hs t u d i e si nr e g a r dt oe ﬃcacy are lacking. The
ACCP points out that while LMWH may oﬀer reproducible
pharmacokinetics and fewer monitoring tests in comparison
with unfractionated heparin the eﬀects of LMWH cannot
be rapidly reversed after its discontinuation [2]. Adult
guidelines from the AHA recommend the administration of
aspirin (325mg/day) within 24–48h of stroke onset [4, 5].
For secondary prevention of AIS recurrence the ACCP
recommends initiation of aspirin therapy (2–5mg/kg/day)
after discontinuation of anticoagulation [9]. For children
with vascular dissection or cardioembolic stroke the ACCP
recommends continuation of anticoagulation with low-
molecular weight heparin or vitamin K antagonists for
3–6 months [9]. The RCP recommends continuation of
aspirin (1–3mg/kg/day) for all children except those with
Moyamoya disease, sickle cell disease, or arterial dissection
[6]. The RCP recommends treatment with anticoagulation
for prevention of secondary AIS in patients with arterial
dissection or cardioembolic stroke [10].
While aspirin is the major antiplatelet agent in clinical
use, the roles for other antiplatelet and anticoagulant med-
ications are under investigation. Adjuvant medications such
asthrombininhibitorsandinhibitorsofplateletglycoprotein
IIb/IIIa (GIIb/IIIa) are being evaluated as monotherapy
and in combination with rt-PA for the treatment of acute
ischemicstroke.Currentstudiesalsoevaluatetheuseofarga-
troban (a thrombin inhibitor) [30], ancrod (a viper-derived
enzyme that cleaves ﬁbrinogen and promotes endogenous
release of plasminogen activator) [31, 32], and desmoteplase
(a bat saliva-derived protease similar in function to human
plasminogen activator) [33, 34]. A recently completed phase
III trial with an intravenous administration of a glycoprotein
IIb/IIIa antagonists, Abciximab, did not demonstrate safety
or eﬃcacy with an increased incidence of intracranial
hemorrhage [35].
3.1.2. Attempts to Prevent Secondary Neuronal Injury. The
literature is not clear how to prevent secondary injury in
AIS. Once blood ﬂow through the MCA was restored, and
measures were taken to protect the ongoing patency of
the vessel, we next considered measures that attempted to
minimize secondary neuronal injury during reperfusion of
the ischemic regions of the brain. Included among these
were (a) the maintenance of adequate cerebral blood ﬂow,
(b) the prevention of hyperglycemia, (c) the continuation
of mild therapeutic hypothermia, and (d) administration of
25% albumin, magnesium salts, and N-methyl-D-aspartate
receptor (NMDA) antagonists.
Maintenance of adequate cerebral perfusion pressure
may be of importance in optimizing neurologic outcome
after AIS if regional autoregulation is lost or in cases of
severe increase in intracranial pressure. While veriﬁcation
of adequacy of cerebral perfusion pressure might have been
optimized with the assistance of an ICP monitor, the risks
of ICP monitor placement in this anticoagulated child were
felt to be prohibitive. In the absence of ICP monitoring we
assumed that our patient probably had at least moderately
increased ICP. Accordingly, we allowed moderate permissive
hypertension, maintained a high osmolarity with hypertonic
saline and mild hypothermia. Fever should be aggressively
treated [36] in AIS, and mild hypothermia has shown to
decreases acute postischemic cerebral edema, a transient
phenomenon that is maximal at 2–4 days postinfarct [37–
39]. However it has been diﬃcult to ascertain a positive
impactinoutcomewithitsuse,andalargerandomizedstudy
is needed [40]. A rebound in intracranial pressure can occur
when rewarming a patient that was hypothermic.
As an indirect monitor of the adequacy of cerebral
perfusion, near infrared spectroscopy (NIRS) monitoring
was applied to both cerebral hemispheres. In the initial
h, regional cerebral oxygen saturation (rSO2) was signiﬁ-
cantly lower in the compromised hemisphere. The stepwise
preload augmentation and addition of norepinephrine to
augment mean arterial pressure only increased the diﬀer-
ences as a “steal” phenomenon by the nonaﬀected area.
Thesubsequentintroductionofmildpermissivehypercapnia
produced an increase and equalization of rSO2 in both
hemispheres.
While these trends in rSO2 could be interpreted to
indicate the restoration of adequate oxygen supply/demand
in the aﬀected hemisphere, prior studies employing NIRS
in the noninvasive monitoring of patients with middle
cerebral artery infarction and cerebral edema suggest that
disappearance of the rSO2 diﬀerence between hemispheres
may indicate worsening cerebral edema and herniation in
the infarcted hemisphere [41]. Computed tomography of
the brain on day 3 and reassuring neurologic examinations
during improving rSO2 values in the aﬀected hemisphere
assured us that the disappearance of the rSO2 gradient
between hemispheres was not due to an ominous process.
The role of NIRS as a noninvasive monitor of cerebral
circulation in pediatric stroke remains to be delineated.
3.1.3. Other Potentially Neuroprotective Pharmacologic Inter-
ventions. Our patient was treated with scheduled infusions
of hypertonic albumin after returning from the angiography
suite. The administration of hypertonic solutions of albumin
is recommended for the treatment of adult ischemic stroke
patients in our institution and is based on studies that
demonstrate improved functional neurologic outcome in
adult patients suﬀering from ischemic stroke [42, 43].
Preclinical and phase I and II trials of the administration
of albumin in acute ischemic stroke suggest that the time
to administration of albumin after ischemic stroke is crit-
ically important (within 4-5h) [44] and that a synergistic
eﬀect may exist when rt-PA is also administered [42]. The
physiologic beneﬁt of albumin administration is believed6 Neurology Research International
to be related to its eﬀect on the endothelium [45–49],
blood viscosity and aggregation [50], interactions with nitric
oxide [51], and inhibition of platelet aggregation [52, 53].
Studiesofalbuminadministrationinexperimentalmodelsof
central nervous system ischemia demonstrate that albumin
administration rapidly improves blood ﬂow in cerebral
vessels with critically reduced ﬂow and clears thrombotic
material adherent to the endothelium in ischemic venules
[53, 54]. While preliminary studies of high dose albumin
administration to AIS patients have been encouraging, the
results of the multicenter, randomized, placebo-controlled
eﬃcacy trial of albumin in acute ischemic stroke—ALIAS
Phase III trial is underway and may provide deﬁnitive
answersontheroleofalbumintherapyinadultAIS.Pediatric
trials on the use of albumin in this setting are still lacking.
Hypertonic albumin administration may induce pulmonary
edema in adults; however it is frequently utilized in pediatric
intensive care in patients with other conditions without
deleterious eﬀects. Decompressive craniotomy is an eﬀective
treatment to treat increased intracranial pressures in patients
w i t he x t e n s i v es t r o k e[ 55].
WeadministeredmemantineHClandmagnesiumsulfate
on a scheduled basis. This is the routine practice of our adult
stroketeam,andtheiradministrationispredicatedonseveral
theoretical principles. The magnesium ion regulates cellular
energy metabolism, vascular tone, and cell membrane ion
transport[56].MagnesiummayregulateATPconcentrations
and is a prerequisite for ATP regeneration after ischemia and
reperfusion [57, 58]. The magnesium ion also blocks the
ion channel of the N-methyl-D-aspartate (NMDA) receptor
in a voltage-dependent fashion, and increasing extracellular
magnesium concentrations in vitro cause noncompetitive
NMDA blockade [59, 60]. In vitro and in vivo models
of focal and global ischemia have demonstrated neuronal
protection that in some instances is as great as that seen
with noncompetitive NMDA antagonists. Magnesium pro-
tects both hippocampal neurons from glutamate-mediated
necrosis and white matter tracts from prolonged ischemia
[61]. Systemic MgCl2 decreased cerebral infarct volume by
20% after permanent middle cerebral artery occlusion in the
rat[62].Memantinehydrochloride,anotherNMDAreceptor
antagonist, was also administered to attenuate reperfusion
injury. While a neuroprotective role has been ascribed to
magnesium sulfate and NMDA receptor antagonists, no data
from human trials have shown conclusive beneﬁt to adult
patients with AIS, and data is therefore certainly lacking to
make recommendations regarding use in pediatric AIS.
4. Conclusions
The case described is a paradigmatic observation of the pos-
sibilityofusinghyperacutetherapiesinchildrenwithstrokes:
early recognition of the event, probable thromboembolism
mechanism, MCA distribution, and rapid consultation with
multiple specialists were crucial factors inﬂuencing the
decision process. Thrombolysis is probably less favorable
when other types of vasculopathy, that most often aﬀect
young children (e.g., basal arterial stenosis), are present.
There is a need to increase awareness of childhood stroke
by pediatricians and emergency room physicians caring
for children with the aim of reducing the time lag from
symptoms to the correct diagnosis. It is imperative to
have in place a preplanned diagnostic algorithm as well as
therapeutic algorithm. Most of emergency departments do
not receive regularly children with stroke. Except in very
speciﬁc cases, it is thus not possible to build autonomic
pediatric stroke centers. Nevertheless, as it is well docu-
mented in the present case report, collaboration between
emergency room physicians, pediatric neurologists, and
physicians working in adult stroke centers should be highly
considered.
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